Epigenetics and Immune Perspectives in Cancer: Overcoming Therapy Resistance
A Special Issue of Biomedicines (ISSN 2227-9059) belonging to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 1522
Editor
Special Issue Information
Dear Colleagues,
Cancer treatment has undergone significant progress in recent years, yet therapy resistance continues to be a formidable barrier to sustained patient remission and overall survival. Mounting evidence indicates that epigenetic changes, such as DNA methylation, histone modifications, and non-coding RNA expression, play a critical role in driving this resistance. In parallel, a deeper understanding of the immune system’s involvement in tumor progression has spurred the development of immunotherapies, which have revolutionized cancer care but face their own obstacles with resistance and immune evasion. Dysregulated epigenetic machinery in the tumor microenvironment can impair immune recognition, shield malignant cells from treatment, and promote therapeutic failure. Numerous studies underscore the interplay between epigenetic alterations, tumor immunogenicity, and antitumor immune responses. Combining epigenetic modulation strategies with innovative immunotherapeutic approaches holds exciting potential to overcome the limitations of traditional treatments and deliver more durable clinical responses.
We are pleased to invite you to contribute to this Special Issue on “Epigenetics and Immune Perspectives in Cancer: Overcoming Therapy Resistance”. By assembling cutting-edge research, we aim to provide a comprehensive overview of how epigenetic regulations and immune mechanisms can be manipulated to augment cancer therapy outcomes. This Special Issue aims to offer an interdisciplinary platform where scientists, clinicians, and other stakeholders can present research on epigenetic and immune-mediated therapies in cancer. We anticipate that this Special Issue will help shape a broader perspective on overcoming therapy resistance and refining current treatment paradigms.
In this Special Issue, original research articles and reviews are welcome. Potential topics include, but are not limited to, the following:
- Epigenetic modifiers (e.g., DNA methyltransferase inhibitors, histone deacetylase inhibitors, and dietary interventions) and synergy with immunotherapies;
- Chromatin remodelers and their roles in immune cell infiltration and tumor microenvironment reprogramming;
- Non-coding RNAs (e.g., microRNAs and lncRNAs) in regulating tumor immunogenicity and resistance mechanisms;
- Novel biomarkers for predicting response or resistance to epigenetic–immune combination therapies;
- Preclinical models and translational studies integrating epigenetic and immune-based interventions;
- Clinical trials and emerging therapeutic strategies targeting epigenetic–immune crosstalk.
We look forward to receiving your contributions.
Dr. Xuemin Lu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epigenetics
- immunotherapy
- therapy resistance
- tumor microenvironment
- DNA methylation
- histone modifications
- dietary intervention
- non-coding RNAs
- immune evasion
- combination therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
